As the coronavirus pandemic intensifies, causing more and more deaths with each passing day, the race to develop treatments to fight this contagious disease is intensifying.
The epidemic has taken its toll worldwide. There are more than 200,000 people infected in the United States and the death toll has risen to 5,000.
Currently, there is no FDA approved treatment for the serious illness caused by SARS-CoV-2. Pharmaceutical / biotechnology companies are racing against the clock to successfully develop vaccines against this disease. Given the alarming levels of spread and severity, certain approved drugs or pipeline candidates are being tested to see if they are effective in treating infected patients.
While the need to cure a large number of infected patients is obvious, it is just as urgent to develop a vaccine to prevent the spread. President Trump wanted to speed up vaccine and treatment approvals to fight the pandemic.
Here, we take a look at the companies, which are leading the race to develop vaccines for this highly infectious disease.
Besides these companies, many other companies have joined the movement. Ology Bioservices Inc. and Inovio Pharmaceuticals Inc. are working together to make the Inovio DNA vaccine for prevention from COVID-19. The Department of Defense (DOD) has awarded Ology Bioservices a contract valued at $ 11.9 million. Several others like Novavax, Inc. NVAX are developing vaccines to fight the disease.
Although the vaccines need some time to be tested, investors will keep an eye on these companies as the pandemic is unlikely to end soon.
Each has been selected by a Zacks expert as the # 1 preferred title to earn + 100% or more in 2020. Each comes from a different industry and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to enter the ground floor.